Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration

H. Robert Bergen, Surendra Dasari, Angela Dispenzieri, John R. Mills, Marina Ramirez-Alvarado, Renee C. Tschumper, Diane F. Jelinek, David R. Barnidge, David L. Murray

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


BACKGROUND: Analytically sensitive techniques for measuring minimal residual disease (MRD) in multiple myeloma (MM) currently require invasive and costly bone marrow aspiration. These methods include immunohistochemistry (IHC), flow cytometry, quantitative PCR, and next-generation sequencing. An ideal MM MRD test would be a serum-based test sensitive enough to detect low concentrations of Ig secreted from multifocal lesions. METHODS: Patient serum with abundant M-protein before treatment was separated on a 1-dimensional SDSPAGE gel, and the Ig light-chain (LC) band was excised, trypsin digested, and analyzed on aQExactive mass spectrometer by LC-MS/MS. We used the peptide's abundance and sequence to identify tryptic peptides that mapped to complementary determining regions of Ig LCs. The clonotypic target tryptic peptides were used to monitor MRD in subsequent serum samples with prior affinity enrichment. RESULTS: Sixty-two patients were tested, 20 with no detectable disease by IHC and 42 with no detectable disease by 6-color flow cytometry. A target peptide that could be monitored was identified in 57 patients (91%). Of these 57, detectable disease by LC-MS/MS was found in 52 (91%). CONCLUSIONS: The ability to use LC-MS/MS to measure disease in patients who are negative by bone marrow-based methodologies indicates that a serumbased approach has more analytical sensitivity and may be useful for measuring deeper responses to MM treatment. The method requires no bone marrow aspiration.

Original languageEnglish (US)
Pages (from-to)243-251
Number of pages9
JournalClinical chemistry
Issue number1
StatePublished - Jan 2016

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration'. Together they form a unique fingerprint.

Cite this